Effect of Octreotide on the Colonic Motility in Pediatric Patients

As mentioned above.

Inclusion Criteria:

- Male or female and undergoing colonic manometry for a routinely accepted indication
including: evaluation of chronic constipation, unexplained abdominal distension
(Should have had previous diagnostic work up), recurrent fecal impaction, post
Hirschsprung's disease repair, chronic intestinal pseudo-obstruction, or suspected
colonic dysmotility of any other cause.

- Children aged 12 months or older who are undergoing colonic motility under the
supervision of Dr. Joseph Croffie at Riley Hospital.

- In the investigator's judgment, parent(s)/guardian(s) is mentally competent to
provide informed consent to participate in the study.

Exclusion Criteria:

- • Subjects with known or suspected allergy to octreotide.

- Subjects with known prolonged corrected QT interval (QTc) Syndrome or highest
risk QTc-Prolonging Agents (including mifepristone).

- Subjects with known history of ventricular arrhythmia.

- Subjects with history of any organ transplant who are taking cyclosporine at the
time of the motility study.

- Subjects with history of small bowel transplant.

- Subjects less than 12 months old.

- Subjects with severe renal impairment

- Subjects with severe hepatic impairment

- Subjects taking bromocriptine, insulin, oral hypoglycemic agents, beta blockers,
calcium channel blockers, quinidine, terfenadine, pimozide, sildenafil,
tadalafil, and any agents to control fluid and electrolyte imbalance